Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVEREL: Avastin + Herceptin/Docetaxel in HER2+ Metastatic Breast Cancer
NCT00391092Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2006
- Primary completion
- Aug 2014
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Progression Free Survival up to 4.75 years. Started Sep 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00391092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00391092.